Physician profile
Beth Winke
NPI 1003812082
$2,526.16
in general payments reported to CMS, 2019-2025
29 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $104 · 2021: $222 · 2022: $538 · 2023: $423 · 2024: $197 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $667.26 | 2019-2025 | Xtampza, Belbuca |
| Electronic Waveform Lab, INC. | $286.98 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.30 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $168.66 | 2019-2023 | Ztlido |
| Abbott Laboratories | $112.29 | 2019-2024 | Proclaim |
| Vertex Pharmaceuticals Incorporated | $103.39 | 2025 | |
| Biodelivery Sciences International, INC. | $95.86 | 2019-2021 | |
| Fidia Pharma USA INC. | $82.66 | 2019-2025 | Triluron, Hymovis |
| Grt US Holding, INC. | $78.39 | 2022 | |
| Pfizer INC. | $64.90 | 2019 | |
| Allergan, INC. | $64.16 | 2019-2020 | |
| Bioventus LLC | $55.95 | 2019-2024 | Durolane |
| Almatica Pharma LLC | $53.73 | 2022 | |
| Pacira Therapeutics, INC. | $53.20 | 2019-2021 | |
| Depuy Synthes Sales INC. | $49.14 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45.11 | 2019-2020 | |
| Shionogi INC | $29.96 | 2019 | |
| Kaleo, INC. | $28.74 | 2019 | |
| Forte Bio-Pharma LLC | $28.71 | 2019-2020 | |
| Abbvie INC. | $27.60 | 2023 | Botox |
| Nevro Corp. | $23.82 | 2024 | Senza |
| Zyla Life Sciences, INC. | $22.87 | 2019 | |
| Averitas Pharma INC. | $22.81 | 2025 | Qutenza |
| Daiichi Sankyo INC. | $17.77 | 2019 | |
| Curonix LLC | $17.69 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Hikma Pharmaceuticals USA | $16.43 | 2022 | |
| Boston Scientific Corporation | $13.59 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.24 | 2022 | |
| Horizon Therapeutics Plc | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Winke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.